Melva sells HCT 10.85: MiMedx Expects To File Its First Investigational New Drug Application In July
June 19, 2014 /PRNewswire/ -- (NASDAQ:MDXG) , an integrated developer ... transition certain indications for use of our micronized products from Section 361 HCT/Ps to licensed biologics." The Company announced the addition of two key executives ... ...
22 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home